Can Big Tech help to de-risk personalized medicine?

In this episode, Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer at Novartis speaks with Pharma Unlimited podcast host, Bertrand Bodson, about ethics and the ability for them to keep up with innovation in the pharma industry.

Does the pharma industry need to re-evaluate the role it plays in tacking the big issues of our time? The topic is up for debate in the next episode of the Pharma Unlimited podcast, where Michelle Nunn, President & CEO at CARE joins Pharma Unlimited podcast host Bertrand Bodson.

In the first episode of our Pharma Unlimited podcast, host Bertrand Bodson and Dr. Peter Lee, Corporate Vice President of Research and Incubation at Microsoft Healthcare, discuss the role Big Tech can play in reducing risk in medicine. This episode looks at the different mindsets between the tech and pharma industries coming together, across the value of intellectual property and more.

Sir John Bell, Regius Professor of Medicine at Oxford University, joins Bertrand Bodson on the latest episode of the Pharma Unlimited podcast. Sir John founded the Wellcome Trust Centre for Human Genetics, and most recently led the program for the AstraZeneca-Oxford COVID-19 vaccine. Sir John tells the story of the Oxford vaccine, and takes a closer look at how the pharma industry might handle risk differently in the future.

Karim Lakhani, Professor of Business Administration at the Harvard Business School, joins Pharma Unlimited host Bertrand Bodson to ask what the pharma and tech industries can learn from each other, and where new risk may arise as they begin to collaborate more closely.